("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh]

Size: px
Start display at page:

Download "("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh]"

Transcription

1 SEARCH STRATEGY PubMed: ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Antilymphocyte Serum"[Mesh] ("regulatory t cells"[title/abstract]) AND "alemtuzumab"[title/abstract] ("T-Lymphocytes, Regulatory"[Mesh]) AND "basiliximab" [Supplementary Concept] ("T-Lymphocytes, Regulatory"[Mesh]) AND "daclizumab" [Supplementary Concept] ("regulatory t cells"[title/abstract]) AND "calcineurin inhibitors"[title/abstract] ("regulatory t cells"[title/abstract]) AND "cyclosporine"[title/abstract] ("regulatory t cells"[title/abstract]) AND "tacrolimus"[title/abstract] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Sirolimus"[Mesh] ("regulatory t cells"[title/abstract]) AND "rapamycin"[title/abstract] ("regulatory t cells"[title/abstract]) AND "everolimus"[title/abstract] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Graft Rejection"[Mesh] ("regulatory t cells"[title/abstract]) AND "acute rejection"[title/abstract] ("regulatory t cells"[title/abstract]) AND "graft function"[title/abstract] Ovid MEDLINE(R): (regulatory t cells and immunosuppression).ab. (regulatory t cells and thymoglobulin).ab.

2 (regulatory t cells and anti-cd25).ab. (regulatory t cells and calcineurin inhibitors).ab. (regulatory t cells and cyclosporine).ab. (regulatory t cells and tacrolimus).ab. (regulatory t cells and sirolimus).ab. (regulatory t cells and rapamycin).ab. (regulatory t cells and everolimus).ab. (regulatory t cells and acute rejection).ab. (regulatory t cells and graft function).ab. ClinicalKey: regulatory t cells and thymoglobulin regulatory t cells and anti-thymphocyte globulin regulatory t cells and alemtuzumab regulatory t cells and basiliximab regulatory t cells and daclizumab regulatory t cells and calcineurin inhibitors regulatory t cells and cyclosporine regulatory t cells and tacrolimus regulatory t cells and mammalian target of rapamycin inhibitors regulatory t cells and sirolimus regulatory t cells and rapamycin regulatory t cells and everolimus

3 regulatory t cells and acute rejection regulatory t cells and graft function Scopus: regulatory t cells and thymoglobulin regulatory t cells and anti-thymphocyte globulin regulatory t cells and alemtuzumab regulatory t cells and basiliximab regulatory t cells and daclizumab regulatory t cells and cyclosporine regulatory t cells and tacrolimus regulatory t cells and sirolimus regulatory t cells and rapamycin regulatory t cells and everolimus regulatory t cells and acute rejection regulatory t cells and graft function Cochrane Central Register of Controlled Trials (CENTRAL): (REGULATORY T CELLS AND IMMUNOSUPPRESSION):TA (REGULATORY T CELLS AND THYMOGLOBULIN):TA (REGULATORY T CELLS AND ANTI-THYMOCYTE GLOBULIN):TA (REGULATORY T CELLS AND ALEMTUZUMAB):TA

4 (REGULATORY T CELLS AND BASILIXIMAB):TA (REGULATORY T CELLS AND DACLIZUMAB):TA (REGULATORY T CELLS AND CYCLOSPORINE):TA (REGULATORY T CELLS AND TACROLIMUS):TA (REGULATORY T CELLS AND SIROLIMUS):TA (REGULATORY T CELLS AND RAPAMYCIN):TA (REGULATORY T CELLS AND EVEROLIMUS):TA (REGULATORY T CELLS AND ACUTE REJECTION):TA (REGULATORY T CELLS AND GRAFT FUNCTION):TA ClinicalTrials.gov: regulatory t cells AND immunosuppression regulatory t cells AND immunosuppressive agents regulatory t cells AND thymoglobulin regulatory t cells AND anti-thymphocyte globulin regulatory t cells AND alemtuzumab regulatory t cells AND basiliximab regulatory t cells AND daclizumab regulatory t cells AND cyclosporine regulatory t cells AND tacrolimus regulatory t cells AND sirolimus regulatory t cells AND rapamycin regulatory t cells AND everolimus

5 regulatory t cells AND acute rejection regulatory t cells AND graft function Meeting abstracts archives: Sociedad Española de Nefrología : manual searches. European Renal Association European Dialysis and Transplantation Association (ERA-EDTA) : manual searches. American Society of Nephrology Kidney Week : manual searches American Transplant Congress 2012, 2013, 2015 y 2016: manual searches. World Transplant Congress 2014: manual searches. TESEO: células t reguladoras linfocitos t reguladores Thèses-en-ligne: céllules t regulatrices

6 DART-Europe E-Theses portal: regulatory t cells Open Access Theses and Dissertations: regulatory t cells

Date: 23 June Context and policy issues:

Date: 23 June Context and policy issues: Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review

More information

Overview of New Approaches to Immunosuppression in Renal Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute

More information

OBJECTIVES. Phases of Transplantation and Immunosuppression

OBJECTIVES. Phases of Transplantation and Immunosuppression Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and

More information

Liver Transplant Immunosuppression

Liver Transplant Immunosuppression Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be

More information

The addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY

The addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin

More information

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression

More information

Tolerance Induction in Transplantation

Tolerance Induction in Transplantation Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent

More information

What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham

What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.

American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant

More information

Heart Transplant: State of the Art. Dr Nick Banner

Heart Transplant: State of the Art. Dr Nick Banner Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression

More information

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80% SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 Immunosuppressive e therapy for kidney transplant in children and young people Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 NICE 2018. All rights reserved. Subject

More information

Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection

Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection 2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant

More information

Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation

Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Trends Fritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation

More information

Belatacept: An Update of Ongoing Clinical Trials

Belatacept: An Update of Ongoing Clinical Trials Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein

More information

9/30/ DISCLOSURES. + First: Why immunosuppress? Transplant Immunosuppression and Prophylaxis

9/30/ DISCLOSURES. + First: Why immunosuppress? Transplant Immunosuppression and Prophylaxis Transplant Immunosuppression and Prophylaxis Sarah Fitz, APN, MSN, ACNP-BC Loyola University Medical Center DISCLOSURES I am not being paid by any entity to endorse a specific product. Any mention of brand

More information

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis(review)

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis(review) Cochrane Database of Systematic Reviews Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis(review) Rodríguez-Perálvarez M, Guerrero-Misas M, Thorburn D,

More information

Fellows Conference 01/21/2016

Fellows Conference 01/21/2016 Fellows Conference 01/21/2016 Outline Basics of transplantation Benefits of transplantation Immunosuppressive medications Anatomy of Renal Transplantation Recipient Selection General medical condition.

More information

Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia

Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department

More information

Literature Review: Transplantation July 2010-June 2011

Literature Review: Transplantation July 2010-June 2011 Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney

More information

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa

More information

PUO in the Immunocompromised Host: CMV and beyond

PUO in the Immunocompromised Host: CMV and beyond PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation

More information

Immunosuppression: evolution in practice and trends,

Immunosuppression: evolution in practice and trends, American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar

More information

Re: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)

Re: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85) January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Immunopathology of T cell mediated rejection

Immunopathology of T cell mediated rejection Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant

More information

The Pennsylvania State University. The Graduate School. College of Medicine THE INFLUENCE OF INDUCTION THERAPY AND DIABETES ON

The Pennsylvania State University. The Graduate School. College of Medicine THE INFLUENCE OF INDUCTION THERAPY AND DIABETES ON The Pennsylvania State University The Graduate School College of Medicine THE INFLUENCE OF INDUCTION THERAPY AND DIABETES ON GRAFT FAILURE AFTER KIDNEY TRANSPLANT A Thesis in Public Health Sciences by

More information

Image: Bruce Wetzel - Harry Schaefer, Wikimedia Commons

Image: Bruce Wetzel - Harry Schaefer, Wikimedia Commons Image: Bruce Wetzel - Harry Schaefer, Wikimedia Commons Martin lversen Section of Lung Transplantation Rigshospitalet Copenhagen Denmark martin.iversen@dadlnet.dk Immunosuppression for the non-transplant

More information

HIV and transplant: obstacles and opportunities

HIV and transplant: obstacles and opportunities HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part

More information

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin

More information

This study is currently recruiting participants.

This study is currently recruiting participants. A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting

More information

1980s-1990s1990s 9/24/2010. David Wojciechowski and. Mary Kennedy-Breiner. Laurie Carlson. Janine Sabatte- Caspillo

1980s-1990s1990s 9/24/2010. David Wojciechowski and. Mary Kennedy-Breiner. Laurie Carlson. Janine Sabatte- Caspillo Factors Influencing Length of Stay: 1980s-1990s1990s Mail the Get Well Cards Home!! Effectively Managing Shorter Length of Stays David Wojciechowski and Higher rejection rates Longer duration of induction

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors

More information

Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications

Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications Original Article Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications G. R. Pourmand 1, S. Dehghani 1*, A. Saraji 1, S. Khaki 1,2, S. H. Mortazavi

More information

Better than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct

Better than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus

More information

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961 CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department

More information

Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham

Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting

More information

Ryszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation

Ryszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation

More information

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? American Journal of Transplantation 2017; 17: 22 27 Wiley Periodicals Inc. Minireview 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society

More information

Introduction. Induction Therapy in Lung Transplantation. Abstract. Key words. José María Borro 1 and Amparo Solé 2

Introduction. Induction Therapy in Lung Transplantation. Abstract. Key words. José María Borro 1 and Amparo Solé 2 Trends in Transplantation Transplant. 2011;5:196-204 Induction Therapy in Lung Transplantation José María Borro 1 and Amparo Solé 2 1 Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario

More information

Innovation In Transplantation:

Innovation In Transplantation: Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were

More information

Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate

Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration

More information

Transplantation in Australia and New Zealand

Transplantation in Australia and New Zealand Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia

More information

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated

More information

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party

More information

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function

More information

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was

More information

Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP

Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP Pancreas transplant recipients are usually under age 50. The majority of pancreas transplants are performed on diabetics, who are generally

More information

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study: An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status

More information

Progress in Pediatric Kidney Transplantation

Progress in Pediatric Kidney Transplantation Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas

More information

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi

More information

Potential Catalysts in Therapeutics

Potential Catalysts in Therapeutics LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted

More information

DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain

DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Silvio Sandrini Division and Chair of Nephrology University

More information

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP

More information

Steroid avoidance or withdrawal for kidney transplant recipients(review)

Steroid avoidance or withdrawal for kidney transplant recipients(review) Cochrane Database of Systematic Reviews Steroid avoidance or withdrawal for kidney transplant recipients(review) HallerMC,RoyuelaA,NaglerEV,PascualJ,WebsterAC Haller MC, Royuela A, Nagler EV, Pascual J,

More information

The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation

The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white

More information

Practical considerations for the use of mtor inhibitors

Practical considerations for the use of mtor inhibitors Diekmann and Campistol Transplantation Research 2015, 4(Suppl 1):5 DOI 10.1186/s13737-015-0029-5 TRANSPLANTATION RESEARCH REVIEW Practical considerations for the use of mtor inhibitors Fritz Diekmann 1,2*

More information

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University

More information

Clinical decisions regarding immunosuppressive

Clinical decisions regarding immunosuppressive PHARMACOLOGIC THERAPIES AND RATIONALES * Stuart D. Russell, MD ABSTRACT This article reviews evidence related to the use of induction therapy and longer-term combination immunosuppressive drug regimens

More information

Immunosuppression is now manageable in the

Immunosuppression is now manageable in the EVOLVING STRATEGIES FOR IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: A REVIEW OF RECENT CLINICAL TRIALS* Stephen J. Tomlanovich, MD, Thomas C. Pearson, MD, DPhil, and Lorenzo Gallon, MD ABSTRACT When using

More information

Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP

Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital

More information

Acute rejection and late renal transplant failure: Risk factors and prognosis

Acute rejection and late renal transplant failure: Risk factors and prognosis Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho

More information

Pleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble

Pleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive

More information

Low toxicity immunosuppressive protocols in renal transplantation. Ron Shapiro

Low toxicity immunosuppressive protocols in renal transplantation. Ron Shapiro LECTURE Low toxicity immunosuppressive protocols in renal transplantation Ron Shapiro Department of Surgery, Director, Renal Transplantation, Thomas E. Starzl, Transplantation Institute University of Pittsburgh,

More information

CAMPATH INDUCTION IN RENAL TRANSPLANTATION. by Kakit Edmond Chan. Thesis is submitted for the degree of MD [Res] of Imperial College London

CAMPATH INDUCTION IN RENAL TRANSPLANTATION. by Kakit Edmond Chan. Thesis is submitted for the degree of MD [Res] of Imperial College London CAMPATH INDUCTION IN RENAL TRANSPLANTATION by Kakit Edmond Chan Thesis is submitted for the degree of MD [Res] of Imperial College London Department of Medicine Imperial College London kkchan 1 Abstract

More information

Emerging Drug List EVEROLIMUS

Emerging Drug List EVEROLIMUS Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine

More information

It s just not that into you:

It s just not that into you: CSHP Clinical Symposium - It s just not that into you: The no-excuses truth to understanding rejection and transplant pharmacology Erica D. Greanya, PharmD Clinical Pharmacy Specialist Solid Organ Transplantation

More information

Pediatric Kidney Transplantation

Pediatric Kidney Transplantation Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida

More information

Manipulation of the Immune Response - Immunomodulation -

Manipulation of the Immune Response - Immunomodulation - Manipulation of the Immune Response - Immunomodulation - Janeway s Immunobiology, 9 th ed., 2017. Ivana Novak Nakir Immune system Immune system make components, cells and organs that act together to defend

More information

Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients

Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients Catherine A. Pennington, 1 Sarah M. Tischer, 1 Eliza Lee, 2 Sun Lee, 2 James Sindelar,

More information

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

More information

Immunosuppressive therapy in liver transplantation

Immunosuppressive therapy in liver transplantation Journal of Hepatology 39 (2003) 664 678 Short Reviews on Liver Transplantation Associate Editor: Didier Samuel Immunosuppressive therapy in liver transplantation Filomena Conti 1, Emmanuel Morelon 2, Yvon

More information

Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017

Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017 Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017 Dr AJ Terblanche Paediatric Gastroenterology and Hepatology Unit, SBAH Paediatric Transplant Unit Wits Donald Gordon Medical

More information

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation Clin Pharmacokinet DOI 10.1007/s40262-017-0573-x REVIEW ARTICLE Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation Marieke van der Zwan 1

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II

More information

Overview of Immunosuppression in Renal Transplantation

Overview of Immunosuppression in Renal Transplantation Chapter 10 Overview of Immunosuppression in Renal Transplantation M. Ghanta, J. Dreier, R. Jacob and I. Lee Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54865

More information

Alfonso H. Santos Jr., Michael J. Casey, and Karl L. Womer

Alfonso H. Santos Jr., Michael J. Casey, and Karl L. Womer Hindawi Journal of Transplantation Volume 217, Article ID 8132672, 1 pages https://doi.org/1.1155/217/8132672 Research Article Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with

More information

Literature Review Transplantation

Literature Review Transplantation Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of

More information

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular

More information

Alemtuzumab Induction in Renal Transplantation

Alemtuzumab Induction in Renal Transplantation original article Induction in Renal Transplantation Michael J. Hanaway, M.D., E. Steve Woodle, M.D., Shamkant Mulgaonkar, M.D., V. Ram Peddi, M.D., Dixon B. Kaufman, M.D., Ph.D., M. Roy First, M.D., Richard

More information

Proton pump inhibitors do not increase the risk of acute rejection

Proton pump inhibitors do not increase the risk of acute rejection ORIGINAL ARTICLE Proton pump inhibitors do not increase the risk of acute rejection G.A.J. van Boekel*, C.H.H. Kerkhofs, F. van de Logt, L.B. Hilbrands Department of Nephrology, Radboud University Medical

More information

Heart Transplantation in the United States,

Heart Transplantation in the United States, American Journal of Transplantation 29; 9 (Part 2): 932 941 Wiley Periodicals Inc. No claim to original US government works Journal compilation C 29 The American Society of Transplantation and the American

More information

By the way, I have a transplant..

By the way, I have a transplant.. By the way, I have a transplant.. Transplant patient for non-transplant surgery David Elliott No relevant disclosures Organ donation in Australia - 2017 Survival rates following organ donation have increased

More information

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH

More information

Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study

Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study Nephrol Dial Transplant (2018) 33: 881 889 doi: 10.1093/ndt/gfx356 Advance Access publication 12 January 2018 Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation

More information

KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients VOL 56, NO 2, AUGUST 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients Margaret Bia, MD, 1 Deborah B. Adey, MD, 2 Roy

More information

Trends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus

Trends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus Trends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus Cytomegalovirus Infections in Everolimus-Based Treatment Tainá Veras de Sandes-Freitas,

More information

clevelandclinic.org/transplant

clevelandclinic.org/transplant carolyn spiotta Pancreas/Kidney Transplant Recipient I feel so fortunate and thankful that I have received a second chance at life. Carolyn Spiotta, 44, Pittsburgh. Carolyn needed a new pancreas and kidney

More information

2017 CST-Astellas Canadian Transplant Fellows Symposium

2017 CST-Astellas Canadian Transplant Fellows Symposium 2017 CST-Astellas Canadian Transplant Fellows Symposium The Future of Transplantation Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto. Dr. Humar received his

More information

Table S1. Clinical outcomes of the acceptable mismatch allocation model.

Table S1. Clinical outcomes of the acceptable mismatch allocation model. Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change

More information

Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation

Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Trends in Transplantation Transplant. 2012;6:28-33 Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Hallvard Holdaas Department

More information

Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up

Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up Transplantation Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up Mohsen Nafar, 1 Behrang Alipour, 2 Pedram Ahmadpoor, 1 Fatemeh Pour-Reza-Gholi,

More information

Combination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So Nephrotoxic As We Thought?

Combination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So Nephrotoxic As We Thought? Trends in Transplant. 2011;5:49-56Helio Tedesco Silva Junior: Calcineurin and mtor inhibitor nephrotoxicity Combination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So

More information

Renal transplantation

Renal transplantation NEPHROLOGY 2008; 13, S37 S43 doi:10.1111/j.1440-1797.2008.00996.x Renal transplantation Date written: November 2006 Final submission: July 2007 Author: Nigel Toussaint GUIDELINES No recommendations possible

More information

OHSU Digital Commons. Oregon Health & Science University. Tysen June Cullen. Scholar Archive. September 2012

OHSU Digital Commons. Oregon Health & Science University. Tysen June Cullen. Scholar Archive. September 2012 Oregon Health & Science University OHSU Digital Commons Scholar Archive September 2012 Body mass index and the development of newonset diabetes mellitus or the worsening of preexisting diabetes mellitus

More information